Skip to main content

Table 4 Relationships between BRAF V600E alone or RET fusion alone or BRAF + TERT or BRAF + RAS mutations and clinicopathological features in PTC patients

From: Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population

CharacteristicsBRAF V600ERET FusionBRAF + TERTBRAF + RAS
Positive (N = 119)Negative (N = 49)P-valuePositive (N = 13)Negative (N = 155)P-valuePositive (N = 10)Negative (N = 158)P-valuePositive (N = 7)Negative (N = 161)P-value
Gender
 Female92 (77.3)39 (79.6)0.7469 (71.4)122 (78.6)0.4287 (70.0)124 (78.5)0.5306 (85.7)125 (77.6)0.614
 Male27 (22.7)10 (20.4) 4 (28.6)33 (21.4) 3 (30.0)34 (21.5) 1 (14.3)36 (22.4) 
Age
 < 4573 (61.3)34 (69.4)0.32411 (85.7)96 (61.7)0.1022 (20.0)105 (66.5)0.003*5 (71.4)102 (63.4)0.679
 ≥ 4546 (38.7)15 (30.6) 2 (14.3)59 (38.3) 8 (80.0)53 (33.5) 2 (28.6)58 (36.6) 
Subtypes
 conventional PTC116 (97.5)40 (81.6)< 0.001*11 (85.7)145 (93.5)0.23010 (100)146 (92.4)0.3667 (100)149 (92.5)0.454
 follicular variant PTC3 (2.5)9 (18.4) 2 (14.3)10 (6.5) 0 (0)12 (7.6) 0 (0)12 (7.5) 
Lymph node metastasis
 Yes107 (89.9)42 (85.7)0.43412 (92.9)137 (88.3)0.6689 (90.0)140 (88.6)0.8936 (85.7)143 (88.8)0.800
 No12 (10.1)7 (24.3) 1 (7.1)18 (11.7) 1 (10.0)18 (11.4) 1 (14.3)18 (11.2) 
AJCC disease stage
 I + II75 (63.0)34 (69.4)0.43211 (85.7)98 (63.0)0.1212 (20.0)107 (67.7)0.002*5 (71.4)104 (64.6)0.711
 III + IV44 (37.0)15 (30.6) 2 (14.3)57 (37.0) 8 (80.0)51 (32.3) 2 (28.6)57 (35.4) 
Lesion number
 Single lesion54 (55.5)24 (75.5)0.67110 (76.9)93 (60.0)0.6552 (20.0)76 (63.9)0.0840 (28.6)78 (62.7)0.015*
 Multiple lesions65 (44.5)25 (24.5) 3 (23.1)62 (40.0) 8 (80.0)82 (36.1) 7 (71.4)83 (37.3) 
  1. Values are presented as number (%). *p < 0.05. BRAF+RAS means BRAF+NRAS and BRAF+HRAS and BRAF+KRAS dual mutations together